STUDY OF A MEDICATION TO POSSIBLY PREVENT OR DELAY THE DEVELOPMENT OF MULTIPLE MYELOMA

Multiple myeloma (MM) is a cancer of the blood that can cause harm to the immune system and painful bodily symptoms. Currently, there is no cure for MM. Before someone develops MM they have a pre-cancer condition known as smoldering multiple myeloma (SMM). Although SMM patients have no symptoms they are at high risk of developing true MM.

- We are conducting this treatment study to test if leflunomide can delay or prevent pre-myeloma from progressing into multiple myeloma
- Since 1998, leflunomide has been FDA-approved for rheumatoid arthritis and safely used by hundreds of thousands of patients
- All study participants will be provided leflunomide for free/at no cost

We are inviting persons:
- Who identify as Black/African American or white/European American.
- Who are eligible to enroll as determined by a doctor

Participation involves:
- Taking the drug leflunomide daily in tablet form, daily for a period between several months to about 2 years
- Providing blood samples and two bone marrow samples for scientific research
- Completing quality-of-life questionnaires

Study participation will continue for about two to three years for appropriate follow-up.

Your participation is voluntary throughout this treatment study, and all information will be kept strictly confidential.

If you are interested in taking part, or for more information, please call Tiffani Gosha, RN, at 626-731-6885, or email at tgosha@coh.org.

APPROVED BY WESTERN IRB
IRB #1301817

City of Hope
CityofHope.org